Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2 Randomized, Multicenter, Open-Label Study Of Iberdomide (CC-220) In Combination With Polatuzumab Vedotin Plus Rituximab Or Tafasitamab Or Rituximab Plus Chemotherapy For Subjects With Relapsed Or Refractory Aggressive B-Cell Lymphoma

NCT04882163 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04882163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04882163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2 Randomized, Multicenter, Open-Label Study Of Iberdomide (CC-220) In Combination With Polatuzumab Vedotin Plus Rituximab Or Tafasitamab Or Rituximab Plus Chemotherapy For Subjects With Relapsed Or Refractory Aggressive B-Cell Lymphoma
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 10, 2021
Completion date
April 7, 2029
Enrollment
0 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell